Turn Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
TTRX$9.92+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| General and administrative | $1,152,996 | $1,303,846 | $2,258,325 | $1,679,591 |
| Research and development | 475,064 | 62,678 | 584,498 | 71,937 |
| Total operating expenses | 1,628,060 | 1,366,524 | 2,842,823 | 1,751,528 |
| Loss from operations | (1,628,060) | (1,366,524) | (2,842,823) | (1,751,528) |
| Other income (expense): | ||||
| Net loss from change in fair value of derivative liability instrument | (3,341,568) | - | (2,644,007) | - |
| Amortization of deferred offering cost | (638,747) | - | (1,116,394) | - |
| Interest income (expense), net | (241,359) | 5,134 | (223,219) | 10,296 |
| Other income | - | 120,975 | 5,578 | 172,260 |
| Total other income (expense) | (4,221,674) | 126,109 | (3,978,042) | 182,556 |
| NET LOSS | $(5,849,734) | $(1,240,415) | $(6,820,865) | $(1,568,972) |
| Basic and diluted net loss per common share | $(0.20) | $(0.05) | $(0.23) | $(0.06) |
| Weighted-average common shares outstanding, basic and diluted | 29,788,040 | 27,494,483 | 29,633,755 | 27,227,013 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.